Cancer & Metabolism. Dec/31/2012; 1: 16-16

Published online Jul/23/2013

PMID: 24280319

PMC: 4178204

doi: 10.1186/2049-3002-1-16

Linking vitamin B1 with cancer cell metabolism

Abstract

Review

Vitamin B1

Thiamine is classified as an essential water-soluble vitamin requiring continuous dietary intake to support carbohydrate metabolism. Thiamine is critical for the activity of four key enzymes in cellular metabolism, pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (α-KGDH) in the tricarboxylic acid (TCA) cycle, transketolase (TKT) within the pentose phosphate pathway (PPP), and branched chain alpha-keto acid dehydrogenase complex (BCKDC) involved in amino acid catabolism. Structurally, thiamine is composed of a thiazole and pyrimidine ring joined together by a methylene bridge (Figure 1). Although thiamine is not the co-enzyme but is converted to the active diphosphate, thiamine pyrophosphate (TPP) form intracellularly, circulating plasma levels of thiamine in healthy individuals range between 10 and 20 nM [1]. The recommended daily intake (RDI) of thiamine for adult men and women is approximately 1–1.5 mg/day [2]. Thiamine is found naturally in many foods including breads, fish, meat, eggs, legumes and milk, as well as being used in fortification of many processed foods (Table 1). In addition, many over-the-counter vitamin supplements contain a significantly large quantity of thiamine representing 100 to 6,600% of the RDI (Table 1).

Table 1

Amount and percent daily value (DV) of thiamine found in food and supplements

Dietary source	Thiamine (mg)	% DV^**
Natural^*
Pork, fresh (3 oz)	0.6	40
Fish (1/2 fillet)	0.3	20
Black beans (1 cup)	0.4	27
Lima beans (1 cup)	0.3	20
Potatoes (1 cup)	0.3	20
Okra (1 cup)	0.2	13
Chicken (1 cup)	0.2	13
Peas (1 cup)	0.2	13
Sunflower seeds (1 cup)	0.7	47
Pistachios (1 oz)	0.2	13
Pecans	0.2	13
Fortified^*
General Mills, total raisin bran (1 cup)	1.6	107
General Mills, total corn flakes (1.3 cups)	1.5	100
Breadcrumbs (1 cup)	1.2	80
White rice (1 cup)	1.1	73
Submarine sandwich, with cold cuts (6" sandwich)	1.0	67
Cornmeal (1 cup)	0.9	60
Supplements
Centrum
Adult	1.5	100
Child (≥4 yrs)	1.5	100
One A Day
Women’s 50+	4.5	300
Women	1.5	100
Girl Teen	2.3	153
Men’s 50+	4.5	300
Men	1.2	80
Solaray
Boy Teen	3.8	250
B Complex	7.5	500
Nature’s Way
Vitamin B1	100	6,667
Nature Made
Vegan B Complex	25	1,667
B Complex	15	1,000

^*Values obtained from United States Department of Agriculture (USDA).

^**The % DV is the percentage of the recommended daily intake (RDI) that each food/supplement contains. The RDI (1–1.5 mg) is determined based on the estimated average requirement of thiamine in that only a small percentage (approximately 2 to 3%) of individuals may experience deficiency [2].

Figure 1

Chemical structures of thiamine (vitamin B1; thiamin) and the active co-enzyme thiamine pyrophosphate (thiamine diphosphate; TPP).

Vitamin B1 homeostasis

The quaternary nitrogen and overall hydrophilicity of thiamine necessitates a carrier-mediated process for absorption and cellular uptake (Figure 2). Two transporters belonging to the SLC19A family, THTR1 (SLC19A2) and THTR2 (SLC19A3) primarily facilitate the transport of thiamine. The other member of the SLC19A family, RFC1 (SLC19A1) facilitates intracellular uptake of reduced folate [3]. Although all three transporters share a high degree of amino acid sequence similarity, RFC1 does not transport thiamine and THTR1/2 has not been shown to transport reduced folate or other organic cations [4,5]. SLC19A2 and SLC19A3 transport thiamine with Km values of 2.5 μM and 27 nM, respectively [6,7]. Intestinal absorption of thiamine has also been described to occur by passive diffusion mechanisms at high concentrations and also via members of the organic cation transporter family [8-10]. Recently, a high affinity carrier-mediated transport mechanism for TPP has been characterized in intestinal cells but no transporter has been identified [11].

Figure 2

Intracellular thiamine homeostasis is initially achieved through the uptake of thiamine (T) by the thiamine transporters THTR1 and THTR2. Once inside the cell, thiamine is converted to the active co-enzyme, thiamine pyrophosphate (TPP) by thiamine pyrophosphokinase-1 (TPK1). Thiamine can than function as a cofactor for the cytoplasmic TKT. Transport of TPP by the thiamine pyrophosphate carrier (TPC) across the mitochondrial membrane supplies cofactor for activity of pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (α-KGDH). Intracellular TPP can also be converted to thiamine monophosphate (TMP) by thiamine pyrophosphatase (TPPase) and subsequently recycled back to thiamine by thiamine monophosphatase (TMPase). Both TMP and TPP can be effluxed out of the cell through the reduced folate carrier (RFC1).

Upon transport into the cell, thiamine is converted to the active co-enzyme thiamine pyrophosphate (diphosphate) by thiamine pyrophosphokinase-1 (TPK1) (Figure 1) [12]. Phosphorylation of thiamine by TPK1 has been shown to be a significant driving force for thiamine uptake along with binding to apo-enzymes [13]. Human TPK1 exists as a homodimer and is expressed ubiquitously with high levels in the kidney, small intestine, and testis [12,14]. In addition to TPP, three other phosphorylated forms have been observed intracellularly in humans, thiamine monphosphate (TMP), thiamine triphosphate (TTP), and adenosine thiamine triphosphate (AThTP) [1]. Although the physiological functions of TMP, TTP, and AThTP have not been ascertained, TPP is the only known thiamine phosphorylate functioning as an enzyme cofactor. Dephosphorylation of intracellular TPP by thiamine pyrophosphatase to TMP can be subsequently recycled back to free thiamine via thiamine monophosphatase [15,16]. SLC19A1 has been shown to efflux the mono and diphosphate ester of thiamine [17]. It is unclear if the dephosphorylation and efflux of thiamine phosphorylates is to regulate intracellular thiamine levels to control cofactor and non-cofactor functions of thiamine phosphorylates. Transport of TPP across the mitochondrial membrane to support PDH and α-KGDH activity is facilitated by the thiamine pyrophosphate carrier (TPC), which is encoded by the SLC25A19 gene [18]. Previously identified as a deoxynucleotide carrier or DNC, homology comparisons to yeast TPP transporter and transport assays have clearly identified TPC as a TPP transporter [18,19].

Thiamine homeostasis genes and cancer

A difference in the expression of thiamine homeostasis genes in cancer has been extensively demonstrated for the thiamine transporter SLC19A3. Using a cDNA array, Liu et al. demonstrated a decrease in SLC19A3 expression in breast cancer compared to corresponding normal tissue [20]. Down-regulation of SLC19A3 was also found in gastric and colon cancer [21,22]. The decrease in expression appears to involve epigenetic repression through hypermethylation and histone deacetylation of the SLC19A3 promoter [21,22]. An elevation of SLC19A3 methylation was detected in the plasma of early- and advanced-stage breast cancer patients as well as gastric cancer [23]. Recently, our group discovered a significant increase in the gene expression of TPK1, SLC19A2, and SLC25A19 in breast cancer tissue samples compared to normal breast tissue [24]. A slight decrease in SLC19A3 gene expression was also found in concordance with previous findings. Upregulation of TPK-1, SLC19A2, SLC25A19 and downregulation of SLC19A3 was also verified in several breast cancer cell lines compared to human mammary epithelial cells (hMECs). Although SLC19A3 expression was repressed, transport assays demonstrated an increase uptake of thiamine in all breast cancer cell lines tested compared to hMECs. Using HPLC to quantify thiamine and thiamine phosphorylates, the overall thiamine status (total of all thiamine forms assayed) was significantly greater in two of the four cancer cell lines evaluated compared to hMECs. Interestingly, all four breast cancer cell lines exhibited a high level of intracellular free thiamine compared to TPP. This may suggest an important non-cofactor role of thiamine in cancer cells or a mechanism to retain the intracellular thiamine supply to support binding to newly synthesized apo-enzyme in progenitor or newly formed daughter cells.

Why tumor cells repress the expression of THTR2 is still unclear. Decreasing expression of one thiamine transporter may not impact overall thiamine status, since transport may still occur via THTR1. This may indicate additional functionality of THTR2 beyond facilitating the intracellular transport of thiamine. When exogenously re-expressing SLC19A3 in gastric cancer cells, a marked decrease in growth rate was found [21]. Liu et al. demonstrated that THTR2 transfection in breast cancer cells increased sensitivity to ionizing radiation and cytotoxicity to doxorubicin [21]. However, it is unclear if the growth-suppressive properties observed in these two studies are mediated through an increase in cellular thiamine concentrations from enhanced transport capacity or due to a novel pro-apoptotic function of THTR2. To this end, Liu et al. established the changes in gene expression when overexpressing THTR2 and when grown in thiamine-deficient media [25]. Several genes involved in oncogenesis were upregulated with THTR2 overexpression that was reduced in the absence of exogenous thiamine [25]. The increase in oncogenic genes with THTR2 re-expression would appear to contradict a role for THTR2 as a tumor suppressor but highlights a potential role for thiamine and THTR2 expression in tumorigenesis.

Though the expression of SLC19A3 appears to be repressed in a number of cancers, Sweet et al. demonstrated that hypoxic exposure resulted in upregulation or re-establishment of SLC19A3 expression in breast cancer cells [26]. A corresponding 2-fold increase in thiamine transport was also observed, suggestive of an increased requirement for thiamine during hypoxic stress [26]. The presence of hypoxic microenvironments in tumors results in an increase in glycolytic activity, primarily controlled by the hypoxia-inducible factor-1 alpha (HIF-1α) transcription factor. Knockdown of HIF-1α attenuated the upregulation, suggesting that SLC19A3 may be an associated gene involved in the adaptive metabolic shift during hypoxic stress [26]. Interestingly, thiamine was shown to reduce hypoxia-mediated apoptosis of rat cardiomyocytes [27]. Thus, increasing transport activity and intracellular thiamine supply may be part of a pro-survival response during hypoxic stress. In this capacity, it is unclear whether thiamine is functioning as a cofactor or non-cofactor. Evidence suggests that the mitochondrial injury associated with hypoxia can lead to an imbalance of reactive oxygen species (ROS) in cancer cells [28-30]. Unchecked, the excess ROS can lead to cellular apoptosis and necrosis and has been exploited as a chemotherapeutic approach [31,32]. Thiamine has direct antioxidant properties as well as being essential for glutathione production [33-35]. Therefore, clarification of thiamine’s role in pro-survival responses to hypoxic stress would be of great significance, given the association of hypoxia with poor patient prognosis.

Thiamine and cancer

It has been hypothesized that a Western diet, characterized in part by excess thiamine supplementation, may be a factor for increased cancer incidence compared to other countries [36]. Thiamine is commonly supplemented in processed foods and readily consumed in over-the-counter vitamin and nutritional supplements in Western countries with generally high cancer incidences. In contrast, Asian and African countries principally consume food that is high in thiaminase, a natural thiamine-degrading enzyme, which may reduce thiamine exposure [36]. Although no direct studies have evaluated this hypothesis, several have attempted to correlate the intake of thiamine and other nutritional components with the risk of cancer. However, like so many other nutritional correlations with cancer incidence, the dietary intake of thiamine and cancer risk has provided conflicting results. Using nutritional questionnaires and a calculated average daily intake level, patients with prostate cancer consume less thiamine than those without cancer suggesting a negative association with cancer risk [37]. A 2008 study examined the relationship between the intake of B vitamins and incidence of breast, endometrial, ovarian, colorectal, and lung cancer in women [38]. No correlation was found between intake of the B vitamins, including thiamine, riboflavin, niacin, and folate, and the incidence of cancer. Interestingly, reduced thiamine intake increased the number of aberrant crypt foci in the colons of rats fed a sucrose-based diet [39]. Patients with severe malnutrition have exhibited Baker’s cyst, osteosarcoma, and submandibular gland cysts that were cured without recurrence after thiamine administration, suggesting a role of thiamine deficiency in tumor development [40].

A limited number of studies and case reports have determined the overall thiamine status in cancer patients. Clinically, thiamine status is quantified biochemically using a TKT assay of whole blood samples [41]. This assay involves measuring the increase in the activity of the thiamine-dependent enzyme TKT after added TPP. If deficient in thiamine, exogenous TPP will stimulate TKT activity, termed the TPP effect. Basu et al. demonstrated that patients with advanced cancer exhibit a greater TPP stimulating effect, suggestive of a reduced thiamine status [42,43]. Similarly, increased TPP effect was characterized in patients with B-chronic lymphocytic leukemia, Burkett’s lymphoma, and acute myelomonocytic leukemia [44,45]. Using an HPLC assay to directly quantify TPP levels in whole blood, Tsao et al. demonstrated a significant decrease of TPP in patients with advanced stages of non-small cell lung cancer [46]. Although the reason for a decrease in thiamine status in the blood is unclear, one study noted that cancer patients had a higher level of thiamine urinary excretion [42]. The authors suggested that the decrease in thiamine status might not be due to reduced dietary intake of thiamine, but an inability to activate thiamine to TPP [42]. However, thiamine status is primarily assayed biochemically in whole blood and limited studies have quantified thiamine/TPP directly in cancer tissue. The reductions in peripheral thiamine/TPP may be a consequence of extensive accumulation and/or utilization by cancer cells. Trebukhina et al. demonstrated that tumor growth resulted in a depletion of tissue vitamin stores and an increase in the TPP-stimulating effect in blood [47]. During tumor growth, cancer cells maintained a constant level of TPP while host liver tissue exhibited a perpetual decline [48]. In post-surgical or autopsy tissues, a 2.5-fold increase in thiamine levels was found in colon adenocarcinomas relative to un-invaded control tissue [49]. Overall these studies strongly suggest a preferential accumulation of thiamine into cancer cells that may be responsible for the alteration in peripheral thiamine status during malignancy.

Aside from the disease itself, chemotherapeutic drugs such as 5-fluorouracil (5-FU) and ifosfamide have been associated with inducing a thiamine-deficient state in patients [50,51]. In most cases, patients exhibit neurological impairment similar to the sequelae observed in thiamine deficiency conditions such as Wernicke’s encephalopathy [51-54]. How these drugs that are structurally unrelated to thiamine are capable of inducing a deficiency is unknown and may involve distinct mechanisms. No change in thiamine or TPP levels was found in patients receiving ifosfamide treatment, suggesting that ifosfamide or a metabolite may inhibit a thiamine-dependent pathway [51,55]. Accumulation of thiamine was found to be increased in cancer cells and rat hepatocytes when treated with 5-FU and doxifluridine [56]. The enhancement in thiamine uptake by 5-FU in cancer cells has been associated with an increase in intracellular TPP while free thiamine remained constant [56]. Treatment of rats for three consecutive days with 5-FU was found to result in an increase in the TPP-stimulating effect on whole blood TKT, and a decrease in liver thiamine stores [57]. Thus, 5-FU appears to decrease peripheral thiamine levels by increasing cellular accumulation and conversion to TPP. Although the mechanism for either drug still needs continued research, high-dose thiamine is capable of reversing the symptoms of thiamine deficiency [50,51,53,54].

Self-supplementation vitamin preparations containing levels of thiamine greater than the RDI are readily accessible and considered to be safe and harmless for patients (Table 1). Although the use of thiamine to treat deficiency-related symptoms attributed to the disease or therapy is warranted, this is currently done with limited comprehension of the role thiamine may contribute towards malignant progression. In light of our knowledge regarding alterations of thiamine homeostasis in cancer, the impact of thiamine supplementation on cancer growth has received minimal research attention. In 2001, Comin-Anduix et al. evaluated the effect of increasing thiamine supplementation in multiples of the RDI on an Ehrlich ascites tumor-mouse model [58]. Their findings indicated a statistically significant stimulatory effect of thiamine supplementation on tumor growth compared to non-supplemented controls. Moderate doses of 12.5 to 37.5 times the RDI had the greatest stimulatory effect, peaking at approximately 250% greater tumor cell proliferation with 25 times the RDI. Interestingly, at values above 75 times the RDI, no change was found in tumor cell proliferation, and a slight decrease was found at 2,500 times the RDI. This observation suggests that there is a specific range in which thiamine supports proliferation. A recent study explored the relationship between a high-fat diet and thiamine levels on the tumor latency in the Tg(MMTVneu) spontaneous breast cancer-tumor mouse model [59]. In this study a normal-fat (NF) diet contained 10% of the calories from fat while the high-fat diet contained 60%. Low thiamine (LT) levels were defined as 2 mg of thiamine per 4,057 kcal and normal thiamine (NT) levels as 6 mg per 4,057 kcal. Tumor latency was significantly longer (295 days) in animals given a NF/LT diet compared with animals on NF/NT (225 days). Interestingly,the delay in tumor latency from LT was abolished when given a high-fat diet. This demonstrates an important interplay of dietary constituents on tumor progression that needs further characterization. Although more research is needed to confirm and evaluate the role of thiamine on disease progression, these studies have significant clinical implications. First, patients requiring thiamine to treat either chemotherapy or disease-associated deficiency should receive high-dose thiamine to avoid enhancing tumor growth. Second, self-supplementation of thiamine by cancer patients should be avoided as the low-to-moderate levels of thiamine may contribute to disease exacerbation.

The importance of thiamine in cancer cell proliferation is highlighted by studies using the thiamine-degrading enzyme thiaminase. Liu et al. demonstrated that the addition of thiaminase into cell culture media containing thiamine had a significant growth inhibitory effect on breast cancer cells [60]. Thiaminase reduced ATP levels in cancer cells, demonstrating thiamine’s key role in support of cancer cell bioenergetics. Moreover, a pegylated version of thiaminase was capable of delaying tumor growth and prolonging survival in an RS4 leukemia xenograft model [61]. Thiamine’s key role in cancer cell metabolism and survival is further demonstrated by studies using the thiamine analog oxythiamine, which functions as an anti-coenzyme and is capable of reducing in vivo and in vitro tumor cell growth [62-64]. Inhibition of TKT by oxythiamine reduces DNA and RNA synthesis through reductions in ribose 5-phosphate (R5P) synthesis, the pentose carbon backbone of all nucleotides. Oxythiamine also has been shown to induce apoptosis in rat PC-12 cells via mitochondria-dependent caspase 3-mediated signaling pathways [65]. The effect on nucleotide synthesis is highlighted by the prominent G1 cell cycle arrest induced by oxythiamine in Ehrlich’s tumor cells [63]. Yang et al. demonstrated that oxythiamine decreases cell migration and invasion in vitro, as well as reduced lung metastases in mice with Lewis lung carcinoma (LLC) [66]. Interestingly, oxythiamine did not reduce the proliferation of LLC cells at concentrations that reduced migration and invasion. The effect of oxythiamine was attributed to a dose-dependent reduction in MMP-2 and MMP-9 activity and expression. This finding suggests that thiamine-dependent pathways have other repercussions on cancer progression in addition to effects on cellular proliferation.

Thiamine-dependent enzymes in cancer

Transketolase

The PPP and in particular the thiamine-dependent enzyme TKT is essential for cancer cells to synthesize large amounts of nucleic acids needed for rapid cellular growth (Figure 3). In normal cells, glucose 6-phosphate enters the PPP and is converted to the nucleotide pentose sugar R5P through the non-thiamine-dependent oxidative branch. If not utilized for de novo nucleotide synthesis, R5P continues into the non-oxidative branch of the PPP where TKT ultimately converts R5P into fructose 6-phosphate (F6P) and glyceraldehyde 3-phosphate (G3P), which re-enters the Embden-Meyerhoff pathway. In contrast, a shift to increased reliance on the non-oxidative PPP for R5P production is found in cancer cells. Boros et al. demonstrated that 98% of the ribose molecules in H441 lung cancer cells were derived through the non-oxidative pathway [67]. Similarly, 85% of the ribose RNA in pancreatic adenocarcinoma cells was from the non-oxidative pathway [62].

Figure 3

Under normal cell metabolism G6P entering the oxidative pentose phosphate pathway (PPP) is converted to ribose 5-phosphate (R5P) and xylulose 5-phsophate (X5P). Both can be further metabolized through the non-oxidative pathway to ultimately form fructose 6-phosphate (F6P) and glyceraldehyde 3-phosphate (G3P) that re-enters the glycolytic pathway to continue catabolism for ATP production. In cancer, reduced activity of M2-PK leads to an excess of F6P and G3P that can be shunted back into the non-oxidative pathway for anabolism. Mediated through transaldolase (TA) and the TPP-dependent enzyme TKT, F6P and G3P are converted to R5P for biosynthesis of nucleotides.

One of the key regulators of glycolysis in cancer cells is the M2 isoform of pyruvate kinase (M2-PK), which catalyzes the conversion of phosphoenolpyruvate to pyruvate. M2-PK is highly expressed in rapidly proliferating cells and is the predominant isoform in cancer [68]. Depending on the metabolic needs, M2-PK oscillates between the active tetramer and inactive dimeric form [69]. The dimer, also known as tumor M2-PK, is the predominant form of PK found in cancer cells and is a potential biomarker for cancer detection [70-73]. The reduced PK activity induces a build-up of phospho-metabolites such as F6P and G3P that are utilized by TKT to produce R5P [74]. Recently, metabolic profiling of gliomas was consistent with an anabolic signature exhibiting reduced M2-PK activity, a build-up of glycolytic intermediates, and high R5P production [75]. Resistance of chronic myeloid leukemia cells to imatinib is associated with an increase in M2-PK expression and an increase in glucose flux into RNA through the non-oxidative PPP [76,77]. Thus, the alteration in glycolysis regulation redirects glucose carbon into thiamine-dependent anabolic pathways that support rapid proliferation and cell survival.

Although the TKT reaction is generally considered to be the result of a single TKT gene, there are two additional TKT isoforms found in the human genome, termed TKT-like 1 (TKTL1) and TKT-like 2 (TKTL2). The increase in substrate flux through the non-oxidative PPP may be supported by an overexpression of TKT isoforms. Immunohistochemical staining of malignant tissues, including breast, lung, colonic, urothelial, ovarian, endometrial, gastric and laryngeal tissues, have all exhibited an overexpression of TKTL1 compared to normal tissues [78-86]. High expression of TKTL1 is correlated with tumor progression and poor patient prognosis [78,79,85,87]. TKTL1 silencing has been shown to suppress growth and proliferation within various tumor cell lines and xenograft models [88-93]. Ectopically overexpressing TKTL1 in head and neck squamous cell carcinoma cells were found to increase cellular proliferation over vector control [94]. Cells overexpressing TKTL1 consumed more glucose, produce greater amounts of G3P, F6P, pyruvate, lactate, and R5P, indicating that TKTL1 promotes an aerobic glycolysis phenotype. Overexpression of TKTL1 has also been associated with activation of the pro-oncogenic HIF-1α under normoxic conditions [94]. The PPP and TKTL1 activity may be important in pro-survival responses by limiting excess production of ROS when challenged with oxidative stresses, such as hypoxia. The glycolytic flux through the oxidative PPP generates nicotinamide adenine dinucleotide phosphate (NADPH), which is essential in regenerating glutathione and for biosynthetic reactions. Increased oxidative stress in cancer cells was demonstrated to suppress M2-PK activity and enhance flux through the oxidative PPP with a concomitant decrease in reduced glutathione levels [95]. Interestingly, knockdown of TKTL1 expression was found to reduce cellular NADPH and glutathione levels with a reciprocal increase in ROS-mediated apoptosis [91]. When exposed to hypoxic stress, reducing TKTL1 expression has resulted in an increase in ROS generation and cell death to glioma cells [96]. It is unclear how TKTL1 activity in the non-oxidative PPP is related to NADPH production generated within the oxidative pathway. TKTL1 activity may contribute to NADPH formation by maintaining continuous flux of glucose carbons through the PPP to avoid intermediate feedback on enzymatic activity.

Although the importance of TKTL1 in cancer proliferation, survival, and metabolism is well established, several reports have suggested that TKTL1 is incapable of enzymatically functioning as a TKT. Homology comparisons of TKTL1 with TKT have noted a deletion of 38 amino acids within the cofactor and catalytic domain, suggesting that TKTL1 is incapable of binding to TPP and carrying out the TKT reaction [97,98]. Schneider et al. engineered a 38 amino acid deletion pseudo-TKTL1 (TKTΔ38) mutant from TKT as a model of TKTL1 to elucidate this issue [99]. No conventional TKT activity of the TKTΔ38 mutant was detectable using a coupled spectrophotometric assay for the conversion of known physiological substrates. Moreover, circular dichroism and proton nuclear magnetic resonance (1H-NMR) spectroscopy indicated that the TKTΔ38 mutant had no associated TPP. Using the same TKTΔ38 mutant system, Meshalkina et al. confirmed the lack of TKT activity in solution and were unable to detect TPP after acid or heat denaturation extraction methods [100]. However, the lack of activity of purified TKTΔ38 in solution contradicts reports describing the TKT activity of TKTL1 when exogenously overexpressed or repressed in cancer cells [76,91,93,94]. Since TKT functions as a homodimer, it is unclear if the TKTΔ38 mutation alters dimer formation. Even if TKTL1 is enzymatically inactive as a homodimer, the expression of TKTL1 in mammalian systems may influence overall TKT activity through heterodimer formation with other TKT isoforms. The lack of TPP binding to the TKTΔ38 mutant does not preclude other thiamine derivatives from binding. The diphosphate group added to thiamine does not participate in the catalytic activity and functions primarily to anchor the cofactor into the apo-enzyme. Other thiamine derivatives with unknown function have been found intracellularly; these may be able to bind within the condensed catalytic site of TKTL1 [1]. Thus, further work is needed to fully understand the biochemistry of TKTL1 in mammalian systems.

How thiamine supplementation impacts carbon flux through the non-oxidative pathway and modulates TKT activity in cancer cells is unknown. Increases in TKT activity may be attributed to an upregulation of enzyme expression. Additionally, thiamine supplementation may also stimulate TKT activity by maintaining a high holo-enzyme fraction by binding to apo-enzymes in progenitor and/or newly generated daughter cells. Recent work describing the benefit of thiamine supplementation in reducing hyperglycemia-induced vascular damage in diabetes may provide some insight. Similar to cancer, hyperglycemia can result in a build-up of phosphometabolites in non-insulin-dependent tissues such as the vascular endothelia. This diverts glucose metabolites into the polyol, hexosamine, advanced glycation, and the diacylglycerol pathways, which are associated with inducing hyperglycemic vascular damage [101]. High-dose thiamine, or the thiamine derivative benfotiamine, stimulate TKT activity and decrease production of toxic metabolites [102-104]. The exposure of high-dose thiamine to human umbilical vein endothelial cells and bovine retinal pericytes cultured in high glucose has been found to result in an increase in TKT mRNA expression and TKT activity [105]. Conversely, thiamine deficiency was found to decrease TKT mRNA levels and reduce TKT activity in neuroblastoma cells [106]. Thus, thiamine appears to have both a regulatory and stimulatory effect on TKT activity.

Pyruvate dehydrogenase

The conversion of pyruvate to acetyl-CoA takes place through a series of reactions mediated by the thiamine-dependent enzyme PDH. Located within the mitochondrial matrix, PDH is a multi-component enzyme complex consisting of three subunits (E1, E2, and E3). As a result of its location at the junction between glycolysis and the TCA cycle, PDH activity functions as a critical gatekeeper for the continued metabolism of glucose (Figure 4). The activity of PDH is tightly regulated through phosphorylation by PDH kinase (PDK) [107]. PDK is a family of four isoenzymes (PDK1, 2, 3 and 4) that function to inhibit PDH activity through ATP-dependent phosphorylation [108-110].

Figure 4

The pyruvate dehydrogenase (PDH) complex converts pyruvate into acetyl-CoA when bound to the co-enzyme, thiamine pyrophosphate (TPP). In cancer, phosphorylation of PDH by pyruvate dehydrogenase kinase isoforms 1 to 4 (PDK1 to 4) inactivates PDH, leading to a reduction, in pyruvate conversion to lactate by lactate dehydrogenase A (LDHA). Inhibition of PDK activity by dichloroacetate (DCA) reduces phosphorylation and induces apoptosis. TPP binding to PDH has also been suggested to inhibit PDK phosphorylation and may explain why high dose thiamine has anti-proliferative effects in a tumor xenograft model. In the oxidative direction, pyruvate is converted to acetyl-CoA by PDH and is continually catabolized to α-ketoglutarate. The thiamine-dependent enzyme alpha-ketoglutarate dehydrogenase (α-KGDH) converts α-ketoglutarate to succinyl-CoA. Cancer cells exploit glutaminolysis to resupply the tricarboxylic acid (TCA) cycle with carbon as α-ketoglutarate. Continuation of the TCA cycle results in anabolic activity to provide precursors for nucleotides, amino acids, and lipids for biomass generation.

In normal cells PDH is active, allowing cells to maintain oxidative metabolism to produce ATP and other components necessary for cell survival and proliferation. However, PDH activity is suppressed in cancer due to downregulation and overexpression of PDK isoforms [111-114]. This truncation of glucose metabolism, highlighted by preferential conversion of pyruvate to lactate, provides cancer cells with a metabolic advantage to maintain rapid proliferation [115]. Thus, an increase in thiamine availability to cancer cells would not be expected to further increase carbon flux through PDH. However, PDH expression is elevated with a reciprocal decrease in PDK isoform expression in tumor-associated stromal tissue, such as fibroblasts and vascular endothelial cells [114,116]. The increased PDH activity in surrounding tissues has been proposed to assist in the detoxification of extracellular lactate produced by cancer cells [116]. This metabolic symbiosis between cancer cells and stromal tissue may be enhanced through increasing thiamine availability, promoting PDH activity in normal tissue surrounding tumors.

Interestingly, restoration of PDH activity in cancer cells has been shown to promote apoptosis and is actively being assessed as a potential therapeutic strategy. One such compound, DCA, has shown considerable promise in multiple cancer types to inhibit PDK-mediated phosphorylation of PDH [117,118]. The re-establishment of glucose oxidation in cancer cells through restored PDH activity results in an increase in mitochondrial ROS and cytochrome C release, ultimately leading to apoptosis [119,120]. Regulation of PDK activity is mediated through the accumulation of metabolic products such as ATP, nicotinamide adenine dinucleotide (NADH) and acetyl-CoA, which stimulate activity, while pyruvate and ADP inhibit when in excess [121]. Another regulator of PDH phosphorylation is the thiamine cofactor TPP, which, when bound to PDH, reduces the rate and extent of PDK-mediated phosphorylation [110]. Thus increasing concentrations of TPP through thiamine supplementation may be pro-apoptotic through restoration of PDH activity in cancer cells. This may explain why a reduction in tumor growth was observed with high-dose thiamine supplementation [58]. The potential of high-dose vitamin B1 to reduce cancer cell growth would be of particular significance and warrants further study.

Alpha-ketoglutarate dehydrogenase

In addition to glucose, cancer cells extensively undergo glutaminolysis, utilizing glutamine as a carbon and nitrogen source [122,123]. Upon entering the cell, glutamine is deaminated to form glutamate and ultimately α-ketoglutarate (α-KG), which serves as an anaplerotic substrate to replenish the TCA cycle (Figure 4). Located in the mitochondria, α-KGDH mediates the conversion of α-KG to succinyl-CoA. With α-KGDH being located at a critical junction that connects glutaminolysis with the TCA cycle, understanding the impact of thiamine supplementation on the functional contribution of α-KGDH to cancer metabolism is highly desirable. Unfortunately there are no reports to date describing changes in α-KGDH expression or activity in cancer.

In the oxidative direction, glutamine derived α-KG entering the TCA cycle is a key carbon backbone for the synthesis of amino acids and nucleotides [122]. Alternatively, glutamine-derived α-KG can undergo reductive decarboxylation through the TCA cycle, forming citrate for lipid biosynthesis [124,125]. This reverse TCA carbon flow would bypass the requirement for α-KGDH activity, allowing the cell to utilize α-KG unabated by changes in thiamine availability. It is unclear how α-KGDH activity is regulated to allow α-KG to move in the reverse direction but has been described to be triggered during hypoxic stress [125,126]. Normally, the activity of α-KGDH is stimulated by low concentrations of calcium and ADP and inhibited at high NADH and succinyl-CoA levels [127]. Reduced activity of α-KGDH has been observed during high oxidative stress that may provide a regulatory switch that allows for reverse TCA carbon flow during hypoxia [128]. Several studies have evaluated the effects of thiamine deficiency on expression and activity of α-KGDH with conflicting results. In human lymphoblasts, fibroblasts and neuroblastoma cells, no change in α-KGDH gene expression and activity were observed during thiamine deficiency [106]. In contrast, in vivo studies reported decreased α-KGDH activities in the neuronal tissues during thiamine deficiency [129,130]. Therefore, clarification of α-KGDH regulation and what impact changes in thiamine availability have on activity and directional flux of the TCA cycle is greatly needed in cancer.

Branched chain alpha-keto acid dehydrogenase complex

Valine, isoleucine, and leucine are essential branched chain amino acids (BCAAs) that can serve as an energy source as well as precursors for amino acid and protein synthesis [131,132]. The metabolism of BCAAs involves transamination to the α-keto acid followed by irreversible oxidative decarboxylation by the thiamine-dependent BCKDC to form an acyl-CoA derivative [132]. The continued catabolic breakdown of BCAA produces acetyl-CoA (from leucine) and succinyl-CoA (from valine and isoleucine) that enter the TCA cycle [132,133]. BCKDC is a multi-component enzyme consisting of three subunits (E1, E2, and E3) and is located in the mitochondria [132]. Similar to PDH, BCKDC activity is regulated through reversible phosphorylation by branched-chain α-keto acid dehydrogenase kinase (BDK) and phosphatase (BDP) [134]. Loss-of-function mutations and BCKDC deficiencies are associated with accumulation of neurotoxic α-keto acids, referred to as maple syrup urine disease (MSUD) that is characterized by a sweet urine odor [135].

In hypermetabolic states such as exercise, sepsis, trauma, and cancer, the release of BCAAs from muscle protein provides a pool of amino acids for the synthesis of priority proteins and/or an important source of oxidative energy [136-138]. Many cancer patients experience involuntary weight loss termed cachexia, which is associated with a loss of skeletal muscle mass [139]. Several in vivo tumor models have demonstrated similar cachetic phenotypes. In Walker 256 carcinoma tumor-bearing rat models, an increase in protein degradation and leucine oxidation in skeletal muscle is observed [140,141]. The increase in BCAA oxidation corresponds with an increase in BCKDC activity in the muscle tissue of Walker 256 and Morris hepatoma 5123 tumor-bearing animals [142-144]. Mediators of proteolysis and BCAA oxidation in muscle tissue of cancer patients may involve pro-inflammatory cytokines [142,145]. Shiraki et al. assessed the effect of TNF-α administration on BCKDC activity in rat liver [146]. In TNF-ɑ-treated rats, BCKDC activity was higher than in control due to reduced BDK-mediated phosphorylation and inactivation. Downregulation of BDK mRNA by the glucocorticoid dexamethasone in rat hepatoma cell lines suggests hormonal regulation of BCAA metabolism and BCKDC activity [147]. A recent metabolomics profiling study of men after androgen deprivation therapy for prostate cancer demonstrated a decrease in the products of the BCKDC reaction, further demonstrating a role for hormone control of BCAA metabolism [148]. Interestingly, the thiamine cofactor TPP is a potent inhibitor (Ki = 4 μM) of BDK-mediated phosphorylation, allowing BCKDC to remain active [149]. High-dose thiamine supplementation increases BCKDC activity in thiamine-responsive MSUD patients [135,150]. However, It is unknown what impact thiamine supplementation has on BCKDC activity and BCAA metabolism in cancer patients. Further research is required to establish if any relationship between thiamine supplementation with BCAA metabolism and cancer cachexia exists.

Conclusions

The alterations in thiamine homeostasis and increase in cancer cell proliferation with thiamine supplementation highlights a significant role for thiamine in cancer. Metabolic studies have provided strong evidence that cancer cells exploit thiamine-dependent enzymes and pathways for anabolic, proliferative, and survival purposes. Unfortunately, how thiamine supplementation impacts the metabolic phenotype of cancer cells is currently hypothetical and is an area of research greatly needed. Refinement of model systems will be absolutely essential in establishing the effects of increasing thiamine supplementation on cancer metabolism and proliferation. Common cell culture media contains super-physiological levels of thiamine that may obscure the importance of thiamine in cancer cell metabolism when using in vitro models. For instance, high glucose DMEM contains 10 μM thiamine, which is approximately 1,000 times greater than circulating plasma levels. Additionally, an organismal approach for understanding the role of thiamine in tumor metabolism will need to include the interplay with other nutrients, the tumor microenvironment, and tumor-stromal tissue demands for thiamine. Once connections between thiamine and cancer cell metabolism are established, new opportunities for therapeutic intervention and dietary modification to reduce disease progression in cancer patients will follow.

Abbreviations

α-KG: α-ketoglutarate; α-KGDH: Alpha-ketoglutarate dehydrogenase; AThTP: Adenosine thiamine triphosphate; BCAA: Branched chain amino acid; BCKDC: Branched chain alpha-keto acid dehydrogenase complex; BDP: α-keto acid dehydrogenase phosphotase; BDK: α-keto acid dehydrogenase kinase; DCA: Dichloroacetate; DMEM: Dulbecco’s modified eagle’s serum; DNC: Deoxynucleotide carrier; DV: Daily value; F6P: Fructose 6-phosphate; 5-FU: 5-fluorouracil; G3P: Glyceraldehyde 3-phosphate; HIF-1α: Hypoxia-inducible factor-1 alpha; hMEC: Human mammary epithelial cell; 1H-NMR: Hydrogen-1-nuclear magnetic resonance; HPLC: High performance liquid chromatography; LDHA: Lactate dehydrogenase A; LLC: Lewis lung carcinoma; LT: Low thiamine; M2-PK: M2 isoform of pyruvate kinase; MSUD: Maple syrup urine disease; NADH: Nicotinamide adenine dinucleotide; NAPDH: Nicotinamide adenine dinucleotide phosphate-oxidase; NF: Normal-fat; NT: Normal thiamine; PDH: Pyruvate dehydrogenase; PDK: Pyruvate dehydrogenase kinase; PPP: Phosphate pathway; RDI: Recommended daily intake; ROS: Reactive oxygen species; R5P: Ribose 5-phosphate; TA: transaldolase; TCA: Tricarboxylic acid; TKT: Transketolase; TKTΔ38: 38 amino acid deletion pseudo-TKTL1; TKTL: TKT-like; TMP: Thiamine monophosphate; TMPase: Thiamine monophosphatase; TNF: Tumor necrosis factor; TPC: Thiamine pyrophosphate carrier; TPK1: Thiamine pyrophosphokinase-1; TPP: Thiamine pyrophosphate; TPPase: Thiamine pyrophosphatase; TTP: Thiamine triphosphate; USDA: United States Department of Agriculture; X5P: Xylulose 5-phsophate.

Competing interests

All authors declare no financial competing interests.

Author’s contributions

JZ conceived the review paper, and outline, and was responsible for revising and critically assessing the intellectual content. RS was responsible for critically reviewing the literature and drafting sections and figures within the manuscript. BH was responsible for critically reviewing the literature and drafting sections and figures within the manuscript. SY was responsible for critically reviewing the literature and drafting sections and figures within the manuscript. All authors read and approved the final manuscript.

Acknowledgement

Dr Jason Zastre was funded by the Georgia Research Alliance, Distinguished Cancer Scholar Award during the preparation of this manuscript.

References

1. GangolfMCzernieckiJRadermeckerMDetryONisolleMJouanCMartinDChantraineFLakayeBWinsPGrisarTBettendorffLThiamine status in humans and content of phosphorylated thiamine derivatives in biopsies and cultured cellsPLoS One20105e13616[PubMed][Google Scholar]
2. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and CholineDietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline1998Washington, DC: National Academies Press (US)
3. GanapathyVSmithSBPrasadPDSLC19: the folate/thiamine transporter familyPfluegers Arch2004447641646[PubMed][Google Scholar]
4. RajgopalAEdmondnsonAGoldmanIDZhaoRSLC19A3 encodes a second thiamine transporter ThTr2Biochim Biophys Acta20011537175178[PubMed][Google Scholar]
5. SubramanianVSMarchantJSParkerISaidHMCell biology of the human thiamine transporter-1 (hTHTR1)J Biol Chem200327839763984[PubMed][Google Scholar]
6. DuttaBHuangWMoleroMKekudaRLeibachFHDevoeLDGanapathyVPrasadPDCloning of the human thiamine transporter, a member of the folate transporter familyJ Biol Chem19992743192531929[PubMed][Google Scholar]
7. SaidHMBalamuruganKSubramanianVSMarchantJSExpression and functional contribution of hTHTR-2 in thiamin absorption in human intestineAm J Physiol2004286G491G498[Google Scholar]
8. HoyumpaAMJrStricklandRSheehanJJYarboroughGNicholsSDual system of intestinal thiamine transport in humansJ Lab Clin Med198299701708[PubMed][Google Scholar]
9. Zielinska-DawidziakMGrajekKOlejnikACzaczykKGrajekWTransport of high concentration of thiamin, riboflavin and pyridoxine across intestinal epithelial cells Caco-2J Nutr Sci Vitaminol200854423429[PubMed][Google Scholar]
10. LemosCFariaAMeirelesMMartelFMonteiroRCalhauCThiamine is a substrate of organic cation transporters in Caco-2 cellsEur J Pharmacol20126823742[PubMed][Google Scholar]
11. NabokinaSMSaidHMA high-affinity and specific carrier-mediated mechanism for uptake of thiamine pyrophosphate by human colonic epithelial cellsAm J Physiol Gastrointest Liver Physiol2012303G389395[PubMed][Google Scholar]
12. NosakaKOnozukaMKakazuNHibiSNishimuraHNishinoHAbeTIsolation and characterization of a human thiamine pyrophosphokinase cDNABiochim Biophys Acta20011517293297[PubMed][Google Scholar]
13. BettendorffLThiamine homeostasis in neuroblastoma cellsNeurochem Int199526295302[PubMed][Google Scholar]
14. BellyeiSSzigetiABoronkaiASzaboZBeneJJanakyTBarnaLSiposKMinikOKravjakAOhmachtRMeleghBZavodszkyPThanGNSumegiBBohnHThanNGCloning, sequencing, structural and molecular biological characterization of placental protein 20 (PP20)/human thiamin pyrophosphokinase (hTPK)Placenta2005263446[PubMed][Google Scholar]
15. RindiGLaforenzaUThiamine intestinal transport and related issues: recent aspectsProc Soc Exp Biol Med2000224246255[PubMed][Google Scholar]
16. ZhaoRGaoFGoldmanIDReduced folate carrier transports thiamine monophosphate: an alternative route for thiamine delivery into mammalian cellsAm J Physiol Cell Physiol2002282C15121517[PubMed][Google Scholar]
17. ZhaoRGaoFWangYDiazGAGelbBDGoldmanIDImpact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cellsJ Biol Chem200127611141118[PubMed][Google Scholar]
18. LindhurstMJFiermonteGSongSStruysEDe LeonardisFSchwartzbergPLChenACastegnaAVerhoevenNMathewsCKPalmieriFBieseckerLGKnockout of Slc25a19 causes mitochondrial thiamine pyrophosphate depletion, embryonic lethality, CNS malformations, and anemiaProc Natl Acad Sci20061031592715932[PubMed][Google Scholar]
19. KangJSamuelsDCThe evidence that the DNC (SLC25A19) is not the mitochondrial deoxyribonucleotide carrierMitochondrion20088103108[PubMed][Google Scholar]
20. LiuSHuangHLuXGolinskiMComesseSWattDGrossmanRBMoscowJADown-regulation of thiamine transporter THTR2 gene expression in breast cancer and is association with resistance to apoptosisMol Cancer Res20031665673[PubMed][Google Scholar]
21. LiuXLamEK-YWangXZhangJ-BChengY-YLamYWNgEK-OYuJChanFK-LJinH-CSungJJ-YPromoter hypermethylation mediates downregulation of thiamine receptor SLC19A3 in gastric cancerTumor Biol200930242248[PubMed][Google Scholar]
22. IkehataMUedaKIwakawaSDifferent involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell linesBiol Pharm Bull201235301307[PubMed][Google Scholar]
23. NgEKLeungCPShinVYWongCLMaESJinHCChuKMKwongAQuantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patientsPLoS One20116e22233[PubMed][Google Scholar]
24. ZastreJAHanberryBSSweetRLMcGinnisACVenutiKRBartlettMGGovindarajanRUp-regulation of vitamin B1 homeostasis genes in breast cancerJ Nutr Biochem2013[Epub ahead of print][PubMed][Google Scholar]
25. LiuSStrombergATaiH-HMoscowJAThiamine transporter gene expression and exogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cellsMol Cancer Res20042477487[PubMed][Google Scholar]
26. SweetRPaulAZastreJHypoxia induced upregulation and function of the thiamine transporter, SLC19A3 in a breast cancer cell lineCancer Biol Ther20101011011111[PubMed][Google Scholar]
27. HeeSBHyukCSYoungCEMin-JeongSKi-ChulHKeunCHHyungCJYangsooJThiamine attenuates hypoxia-induced cell death in cultured neonatal rat cardiomyocytesMol Cells200418133140[PubMed][Google Scholar]
28. ChandelNSMaltepeEGoldwasserEMathieuCESimonMCSchumackerPTMitochondrial reactive oxygen species trigger hypoxia-induced transcriptionProc Natl Acad Sci1998951171511720[PubMed][Google Scholar]
29. LiuLWiseDRDiehlJASimonMCHypoxic reactive oxygen species regulate the integrated stress response and cell survivalJ Biol Chem20082833115331162[PubMed][Google Scholar]
30. GuzyRDHoyosBRobinEChenHLiuLMansfieldKDSimonMCHammerlingUSchumackerPTMitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensingCell Metab20051401408[PubMed][Google Scholar]
31. TrachoothamDAlexandreJHuangPTargeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?Nat Rev Drug Discov20098579591[PubMed][Google Scholar]
32. SimonHUHaj-YehiaALevi-SchafferFRole of reactive oxygen species (ROS) in apoptosis inductionApoptosis20005415418[PubMed][Google Scholar]
33. LukienkoPIMel’nichenkoNGZverinskiiIVZabrodskayaSVAntioxidant properties of thiamineBull Exp Biol Med2000130874876[PubMed][Google Scholar]
34. SchmidUStopperHHeidlandASchuppNBenfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitroDiabetes Metab Res Rev200824371377[PubMed][Google Scholar]
35. MartinPRSingletonCKHiller-SturmhofelSThe role of thiamine deficiency in alcoholic brain diseaseAlcohol Res Health200327134142[PubMed][Google Scholar]
36. BorosLGPopulation thiamine status and varying cancer rates between western, Asian and African countriesAnticancer Res20002022452248[PubMed][Google Scholar]
37. KaulLHeshmatMYKoviJJacksonMAJacksonAGJonesGWEdsonMEnterlineJPWorrellRGPerrySLThe role of diet in prostate cancerNutr Cancer19879123128[PubMed][Google Scholar]
38. KabatGCMillerABJainMRohanTEDietary intake of selected B vitamins in relation to risk of major cancers in womenBr J Cancer200899816821[PubMed][Google Scholar]
39. BruceWRFurrerRShangariNO’BrienPJMedlineAWangYMarginal dietary thiamin deficiency induces the formation of colonic aberrant crypt foci (ACF) in ratsCancer Lett2003202125129[PubMed][Google Scholar]
40. LeeBYYanamandraKBocchiniJAJrThiamin deficiency: a possible major cause of some tumors?Oncol Rep20051415891592[PubMed][Google Scholar]
41. ChamberlainBRButteryJEPannallPRA stable reagent mixture for the whole blood transketolase assayAnn Clin Biochem199633352354[PubMed][Google Scholar]
42. BasuTKDickersonJWTThe thiamin status of early cancer patients with particular reference to those with breast and bronchial carcinomasOncol197633250252[PubMed][Google Scholar]
43. BasuTKDickersonJWRavenRWWilliamsDCThe thiamine status of patients with cancer as determined by the red cell transketolase activityInt J Vitam Nutr Res1974445358[PubMed][Google Scholar]
44. van ZaanenHCvan der LelieJThiamine deficiency in hematologic malignant tumorsCancer19926917101713[PubMed][Google Scholar]
45. SeligmannHLeviRKonijnAMProkocimerMThiamine deficiency in patients with B-chronic lymphocytic leukaemia: a pilot studyPostgrad Med J200177582585[PubMed][Google Scholar]
46. TsaoS-MYinM-CLiuW-HOxidant stress and B vitamins status in patients with non-small cell lung cancerNutr Cancer200759813[PubMed][Google Scholar]
47. TrebukhinaRVOstrovskyYMShapotVSMikhaltsevichGNTumanovVNTurnover of [14C]thiamin and activities of thiamin pyrophosphate-dependent enzymes in tissues of mice with Ehrlich ascites carcinomaNutr Cancer19846260273[PubMed][Google Scholar]
48. TrebukhinaRVOstrovsky YuMShapotVSPetushokVGVelichkoMGTumanovVNMikhaltsevichGNThiamine metabolism in the liver of mice with Ehrlich ascites carcinomaNeoplasma198229257268[PubMed][Google Scholar]
49. BakerHFrankOChenTFeingoldSDeAngelisBBakerERElevated vitamin levels in colon adenocarcinoma as compared with metastatic liver adenocarcinoma from colon primary and normal adjacent tissueCancer19814728832886[PubMed][Google Scholar]
50. AksoyMBasuTKBrientJDickersonJWThiamin status of patients treated with drug combinations containing 5-fluorouracilEur J Cancer19801610411045[PubMed][Google Scholar]
51. BuesaJMGarcia-TeijidoPLosaRFraJTreatment of ifosfamide encephalopathy with intravenous thiaminClin Cancer Res2003946364637[PubMed][Google Scholar]
52. AmesBLewisLDChaffeeSKimJMorseRIfosfamide-induced encephalopathy and movement disorderPediatr Blood Cancer201054624626[PubMed][Google Scholar]
53. HamadaniMAwanFRole of thiamine in managing ifosfamide-induced encephalopathyJ Oncol Pharm Pract200612237239[PubMed][Google Scholar]
54. LombardiGZustovichFNicolettoMODonachMPastorelliDImportant role of thiamine in preventing ifosfamide-induced encephalopathyJ Oncol Pharm Pract201016135136[PubMed][Google Scholar]
55. LosaRSierraMIFernándezABlancoDBuesaJMDetermination of thiamine and its phosphorylated forms in human plasma, erythrocytes and urine by HPLC and fluorescence detection: a preliminary study on cancer patientsJ Pharm Biomed Anal20053710251029[PubMed][Google Scholar]
56. HeierMSDornishJMEffect of the fluoropyrimidines 5-fluorouracil and doxifluridine on cellular uptake of thiaminAnticancer Res1989910731077[PubMed][Google Scholar]
57. BasuTKAksoyMDickersonJWEffects of 5-fluorouracil on the thiamin status of adult female ratsChemother1979257076[PubMed][Google Scholar]
58. Comin-AnduixBBorenJMartinezSMoroCCentellesJJTrebukhinaRPetushokNLeeW-NPBorosLGCascanteMThe effect of thiamine supplementation on tumour proliferation. A metabolic control analysis studyEur J Biochem200126841774182[PubMed][Google Scholar]
59. DailyALiuSBhatnagarSKarabakhtsianRGMoscowJALow-thiamine diet increases mammary tumor latency in FVB/N-Tg(MMTVneu) miceInt J Vitam Nutr Res201282298302[PubMed][Google Scholar]
60. LiuSMonksNRHanesJWBegleyTPYuHMoscowJASensitivity of breast cancer cell lines to recombinant thiaminase ICancer Chemother Pharmacol201066171179[PubMed][Google Scholar]
61. DailyALiuSBaeYBhatnagarSMoscowJALinear chain PEGylated recombinant Bacillus thiaminolyticus thiaminase I enzyme has growth inhibitory activity against lymphoid leukemia cell linesMol Cancer Ther20111015631570[PubMed][Google Scholar]
62. BorosLGPuigjanerJCascanteMLeeW-NPBrandesJLBassilianSYusufFIWilliamsRDMuscarellaPMelvinWSSchirmerWJOxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferationCancer Res19975742424248[PubMed][Google Scholar]
63. RaisBCominBPuigjanerJBrandesJLCreppyESaboureauDEnnamanyRLeeW-NPBorosLGCascanteMOxythiamin and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich’s tumor cells through inhibition of the pentose cycleFEBS Lett1999456113118[PubMed][Google Scholar]
64. Ramos-MontoyaALeeWNBassilianSLimSTrebukhinaRVKazhynaMVCiudadCJNoeVCentellesJJCascanteMPentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancerInt J Cancer200611927332741[PubMed][Google Scholar]
65. ChornyySParkhomenkoJChornaNThiamine deficiency caused by thiamine antagonists triggers upregulation of apoptosis inducing factor gene expression and leads to caspase 3-mediated apoptosis in neuronally differentiated rat PC-12 cellsActa Biochim Pol200754315322[PubMed][Google Scholar]
66. YangCMLiuYZLiaoJWHuMLThe in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanisms of actionClin Exp Metastasis201027341349[PubMed][Google Scholar]
67. BorosLGTordayJSLimSBassilianSCascanteMLeeW-NPTransforming growth factor beta 2 promotes glucose carbon incorporation into nucleic acid ribose through the nonoxidative pentose cycle in lung epithelial carcinoma cellsCancer Res20006011831185[PubMed][Google Scholar]
68. ChristofkHRVander HeidenMGHarrisMHRamanathanAGersztenREWeiRFlemingMDSchreiberSLCantleyLCThe M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growthNat2008452230233[PubMed][Google Scholar]
69. MazurekSPyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cellsInt J Biochem Cell Biol201143969980[PubMed][Google Scholar]
70. MazurekSBoschekCBHugoFEigenbrodtEPyruvate kinase type M2 and its role in tumor growth and spreadingSemin Cancer Biol200515300308[PubMed][Google Scholar]
71. EigenbrodtEBasenauDHolthusenSMazurekSFischerGQuantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomasAnticancer Res19971731533156[PubMed][Google Scholar]
72. SchneiderJMorrHVelcovskyHGWeisseGEigenbrodtEQuantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseasesCancer Detect Prev200024531535[PubMed][Google Scholar]
73. HathurusingheHRGoonetillekeKSSiriwardenaAKCurrent status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancyAnn Surg Oncol20071427142720[PubMed][Google Scholar]
74. MazurekSBoschekCBEigenbrodtEThe role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapyJ Bioenerg Biomembr199729315330[PubMed][Google Scholar]
75. ChinnaiyanPKensickiEBloomGPrabhuASarcarBKahaliSEschrichSQuXForsythPGilliesRThe metabolomic signature of malignant glioma reflects accelerated anabolic metabolismCancer Res20127258785888[PubMed][Google Scholar]
76. ZhaoFMancusoABuiTVTongXGruberJJSwiderCRSanchezPVLumJJSayedNMeloJVPerlAECarrollMTuttleSWThompsonCBImatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha -induced metabolic reprogramingOncog20102929622972[PubMed][Google Scholar]
77. SerkovaNBorosLGDetection of resistance to imatinib by metabolic profiling: clinical and drug development implicationsAm J Pharmacogenomics20055293302[PubMed][Google Scholar]
78. LangbeinSZerilliMzur HausenAStaigerWRensch-BoschertKLukanNPopaJTernulloMPSteidlerAWeissCGrobholzRWillekeFAlkenPStassiGSchubertPCoyJFExpression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpretedBr J Cancer200694578585[PubMed][Google Scholar]
79. Diaz-MoralliSTarrado-CastellarnauMAlendaCCastellsACascanteMTransketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formationPLoS One20116e25323[PubMed][Google Scholar]
80. StaigerWICoyJFGrobholzRHofheinzRDLukanNPostSSchwarzbachMHWillekeFExpression of the mutated transketolase TKTL1, a molecular marker in gastric cancerOncol Rep200616657661[PubMed][Google Scholar]
81. FoeldiMStickelerEBauLKretzOWatermannDGitschGKayserGZur HausenACoyJFTransketolase protein TKTL1 overexpression: a potential biomarker and therapeutic target in breast cancerOncol Rep200717841845[PubMed][Google Scholar]
82. KrockenbergerMEngelJBSchmidtMKohrenhagenNHauslerSFDombrowskiYKappMDietlJHonigAExpression of transketolase-like 1 protein (TKTL1) in human endometrial cancerAnticancer Res20103016531659[PubMed][Google Scholar]
83. SchultzHKaehlerDBranscheidDVollmerEZabelPGoldmannTTKTL1 is overexpressed in a large portion of non-small cell lung cancer specimensDiagn Pathol2008335[PubMed][Google Scholar]
84. KrockenbergerMHonigARiegerLCoyJFSutterlinMKappMHornEDietlJKammererUTransketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastasesInt J Gynecol Cancer200717101106[PubMed][Google Scholar]
85. VolkerHUScheichMSchmausserBKammererUEckMOverexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomasEur Arch Otorhinolaryngol200726414311436[PubMed][Google Scholar]
86. SchmidtMVoelkerH-UKappMKrockenbergerMDietlJKammererUGlycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PKJ Cancer Res Clin Oncol2010136219225[PubMed][Google Scholar]
87. SchwaabJHorisbergerKStrobelPBohnBGencerDKahlerGKienlePPostSWenzFHofmannWKHofheinzRDErbenPExpression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapyBMC Cancer201111363[PubMed][Google Scholar]
88. HuL-HYangJ-HZhangD-TZhangSWangLCaiP-CZhengJ-FHuangJ-SThe TKTL1 gene influences total transketolase activity and cell proliferation in human colon cancer LoVo cellsAnticancer Drugs200718427433[PubMed][Google Scholar]
89. ZhangSYueJXYangJHCaiPCKongWJOverexpression of transketolase protein TKTL1 is associated with occurrence and progression in nasopharyngeal carcinomaCancer Biol Ther20087517522[PubMed][Google Scholar]
90. ChenHYueJ-XYangS-HDingHZhaoR-WZhangSOverexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancerJ Exp Clin Cancer Res20092843[PubMed][Google Scholar]
91. XuXZur HausenACoyJFLocheltMTransketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cellsInt J Cancer200912413301337[PubMed][Google Scholar]
92. ZhangSYangJ-HGuoC-KCaiP-cGene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cellsCancer Lett2007253108114[PubMed][Google Scholar]
93. YuanWWuSGuoJChenZGeJYangPHuBChenZSilencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivoCancer Biol Ther20109710716[PubMed][Google Scholar]
94. SunWLiuYGlazerCAShaoCBhanSDemokanSZhaoMRudekMAHaPKCalifanoJATKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilizationClin Cancer Res201016857866[PubMed][Google Scholar]
95. AnastasiouDPoulogiannisGAsaraJMBoxerMBJiangJKShenMBellingerGSasakiATLocasaleJWAuldDSThomasCJVander HeidenMGCantleyLCInhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responsesSci201133412781283[PubMed][Google Scholar]
96. WankaCSteinbachJPRiegerJTp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasisJ Biol Chem20122873343633446[PubMed][Google Scholar]
97. MitschkeLParthierCSchroder-TittmannKCoyJLudtkeSTittmannKThe crystal structure of human transketolase and new insights into its mode of actionJ Biol Chem20102853155931570[PubMed][Google Scholar]
98. MaslovaAOMeshalkinaLEKochetovGAComputer modeling of transketolase-like protein, TKTL1, a marker of certain tumor tissuesBiochem201277296299[PubMed][Google Scholar]
99. SchneiderSLudtkeSSchroder-TittmannKWechslerCMeyerDTittmannKA delta38 deletion variant of human transketolase as a model of transketolase-like protein 1 exhibits no enzymatic activityPLoS One20127e48321[PubMed][Google Scholar]
100. MeshalkinaLEDrutsaVLKorolevaONSolovjevaONKochetovGAIs transketolase-like protein, TKTL1, transketolase?Biochim Biophys Acta20131832387390[PubMed][Google Scholar]
101. BrownleeMBiochemistry and molecular cell biology of diabetic complicationsNat2001414813820[PubMed][Google Scholar]
102. Babaei-JadidiRKarachaliasNAhmedNBattahSThornalleyPJPrevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamineDiab20035221102120[PubMed][Google Scholar]
103. HammesHPDuXEdelsteinDTaguchiTMatsumuraTJuQLinJBierhausANawrothPHannakDNeumaierMBergfeldRGiardinoIBrownleeMBenfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathyNat Med20039294299[PubMed][Google Scholar]
104. RabbaniNThornalleyPJEmerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathyDiab Obes Metab201113577583[PubMed][Google Scholar]
105. BerroneEBeltramoESolimineCApeAUPortaMRegulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucoseJ Biol Chem200628193079313[PubMed][Google Scholar]
106. PekovichSRMartinPRSingletonCKThiamine deficiency decreases steady-state transketolase and pyruvate dehydrogenase but not alpha-ketoglutarate dehydrogenase mRNA levels in three human cell typesJ Nutr1998128683687[PubMed][Google Scholar]
107. PatelMSRocheTEMolecular biology and biochemistry of pyruvate dehydrogenase complexesFASEB J1990432243233[PubMed][Google Scholar]
108. KorotchkinaLGPatelMSSite specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenaseJ Biol Chem20012763722337229[PubMed][Google Scholar]
109. HolnessMJSugdenMCRegulation of pyruvate dehydrogenase complex activity by reversible phosphorylationBiochem Soc Trans20033111431151[PubMed][Google Scholar]
110. KolobovaETuganovaABoulatnikovIPopovKMRegulation of pyruvate dehydrogenase activity through phosphorylation at multiple sitesBiochem J20013586977[PubMed][Google Scholar]
111. LuCWLinSCChienCWLinSCLeeCTLinBWLeeJCTsaiSJOverexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancerAm J Pathol201117914051414[PubMed][Google Scholar]
112. HurHXuanYKimYBLeeGShimWYunJHamIHHanSUExpression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic targetInt J Oncol2013424454[PubMed][Google Scholar]
113. BaumunkDReicheltUHildebrandtJKrauseHEbbingJCashHMillerKSchostakMWeikertSExpression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC)World J Urol201216[PubMed][Google Scholar]
114. KoukourakisMIGiatromanolakiASivridisEGatterKCHarrisALPyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stromaNeoplasia2005716[PubMed][Google Scholar]
115. McFateTMohyeldinALuHThakarJHenriquesJHalimNDWuHSchellMJTsangTMTeahanOZhouSCalifanoJAJeoungNHHarrisRAVermaAPyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cellsJ Biol Chem20082832270022708[PubMed][Google Scholar]
116. KoukourakisMIGiatromanolakiAHarrisALSivridisEComparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stromaCancer Res200666632637[PubMed][Google Scholar]
117. MichelakisEDWebsterLMackeyJRDichloroacetate (DCA) as a potential metabolic-targeting therapy for cancerBr J Cancer200899989994[PubMed][Google Scholar]
118. MadhokBMYeluriSPerrySLHughesTAJayneDGDichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cellsBr J Cancer201010217461752[PubMed][Google Scholar]
119. BonnetSArcherSLAllalunis-TurnerJHaromyABeaulieuCThompsonRLeeCTLopaschukGDPuttaguntaLBonnetSHarryGHashimotoKPorterCJAndradeMAThebaudBMichelakisEDA mitochondria-K + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growthCancer Cell2007113751[PubMed][Google Scholar]
120. XieJWangBSYuDHLuQMaJQiHFangCChenHZDichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cellsInt J Oncol201138409417[PubMed][Google Scholar]
121. RocheTEHiromasaYPyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancerCell Mol Life Sci200764830849[PubMed][Google Scholar]
122. DeBerardinisRJMancusoADaikhinENissimIYudkoffMWehrliSThompsonCBBeyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesisProc Natl Acad Sci USA20071041934519350[PubMed][Google Scholar]
123. DeBerardinisRJLumJJHatzivassiliouGThompsonCBThe biology of cancer: metabolic reprogramming fuels cell growth and proliferationCell Metab200871120[PubMed][Google Scholar]
124. MullenARWheatonWWJinESChenPHSullivanLBChengTYangYLinehanWMChandelNSDeBerardinisRJReductive carboxylation supports growth in tumour cells with defective mitochondriaNat2012481385388[Google Scholar]
125. MetalloCMGameiroPABellELMattainiKRYangJHillerKJewellCMJohnsonZRIrvineDJGuarenteLKelleherJKVander HeidenMGIliopoulosOStephanopoulosGReductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxiaNat2012481380384[Google Scholar]
126. WiseDRWardPSShayJECrossJRGruberJJSachdevaUMPlattJMDeMatteoRGSimonMCThompsonCBHypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viabilityProc Natl Acad Sci USA20111081961119616[PubMed][Google Scholar]
127. SmithCMBrylaJWilliamsonJRRegulation of mitochondrial alpha-ketoglutarate metabolism by product inhibition at alpha-ketoglutarate dehydrogenaseJ Biol Chem197424914971505[PubMed][Google Scholar]
128. StarkovAAAn update on the role of mitochondrial alpha-ketoglutarate dehydrogenase in oxidative stressMol Cell Neurosci2013551316[PubMed][Google Scholar]
129. ButterworthRFGiguereJFBesnardAMActivities of thiamine-dependent enzymes in two experimental models of thiamine-deficiency encephalopathy. 2. alpha-Ketoglutarate dehydrogenaseNeurochem Res198611567577[PubMed][Google Scholar]
130. ParkerWDJrHaasRStumpfDAParksJEgurenLAJacksonCBrain mitochondrial metabolism in experimental thiamine deficiencyNeurol19843414771481[PubMed][Google Scholar]
131. PlatellCKongSEMcCauleyRHallJCBranched-chain amino acidsJ Gastroenterol Hepatol200015706717[PubMed][Google Scholar]
132. HarperAEMillerRHBlockKPBranched-chain amino acid metabolismAnnu Rev Nutr19844409454[PubMed][Google Scholar]
133. HarrisRAJoshiMJeoungNHObayashiMOverview of the molecular and biochemical basis of branched-chain amino acid catabolismJ Nutr20051351527S1530S[PubMed][Google Scholar]
134. HarrisRAJoshiMJeoungNHMechanisms responsible for regulation of branched-chain amino acid catabolismBiochem Biophys Res Commun2004313391396[PubMed][Google Scholar]
135. ChuangDTChuangJLWynnRMLessons from genetic disorders of branched-chain amino acid metabolismJ Nutr2006136243S249S[PubMed][Google Scholar]
136. ShimomuraYMurakamiTNakaiNNagasakiMHarrisRAExercise promotes BCAA catabolism: effects of BCAA supplementation on skeletal muscle during exerciseJ Nutr20041341583S1587S[PubMed][Google Scholar]
137. BaracosVEMackenzieMLInvestigations of branched-chain amino acids and their metabolites in animal models of cancerJ Nutr2006136237S242S[PubMed][Google Scholar]
138. De BandtJPCynoberLTherapeutic use of branched-chain amino acids in burn, trauma, and sepsisJ Nutr2006136308S313S[PubMed][Google Scholar]
139. MacDonaldNEassonAMMazurakVCDunnGPBaracosVEUnderstanding and managing cancer cachexiaJ Am Coll Surg2003197143161[PubMed][Google Scholar]
140. GoodladGAClarkCMLeucine metabolism in skeletal muscle of the tumour-bearing ratEur J Cancer19801611531162[PubMed][Google Scholar]
141. ArgilesJMLopez-SorianoFJThe oxidation of leucine in tumour-bearing ratsBiochem J1990268241244[PubMed][Google Scholar]
142. SiddiquiRAWilliamsJFThe regulation of fatty acid and branched-chain amino acid oxidation in cancer cachectic rats: a proposed role for a cytokine, eicosanoid, and hormone trilogyBiochem Med Metab Biol1989427186[PubMed][Google Scholar]
143. ArgilesJMLopez-SorianoFJOxidation of branched-chain amino acids in tumor-bearing ratsBiochem Soc Trans19891710441045[PubMed][Google Scholar]
144. PaxtonKWardLCWilcePAAmino acid oxidation in the tumor-bearing ratCancer Biochem Biophys19889343351[PubMed][Google Scholar]
145. BaracosVERegulation of skeletal-muscle-protein turnover in cancer-associated cachexiaNutr20001610151018[PubMed][Google Scholar]
146. ShirakiMShimomuraYMiwaYFukushimaHMurakamiTTamuraTTamuraNMoriwakiHActivation of hepatic branched-chain alpha-keto acid dehydrogenase complex by tumor necrosis factor-alpha in ratsBiochem Biophys Res Commun2005328973978[PubMed][Google Scholar]
147. HuangYSChuangDTDown-regulation of rat mitochondrial branched-chain 2-oxoacid dehydrogenase kinase gene expression by glucocorticoidsBiochem J1999339Pt 3503510[PubMed][Google Scholar]
148. SaylorPJKarolyEDSmithMRProspective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancerClin Cancer Res20121836773685[PubMed][Google Scholar]
149. LauKSFataniaHRRandlePJRegulation of the branched chain 2-oxoacid dehydrogenase kinase reactionFEBS Lett19821445762[PubMed][Google Scholar]
150. DannerDJWheelerFBLemmonSKElsasLJ2ndIn vivo and in vitro response of human branched chain alpha-ketoacid dehydrogenase to thiamine and thiamine pyrophosphatePediatr Res197812235238[PubMed][Google Scholar]